๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HER2-positive Breast Cancer
Clinical trial register · China

HER2-positive Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Guangzhou 14 Shanghai 8 Hefei 7 Bengbu 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shu Wang7 Sichuan Baili Pharmaceutical Co., Ltd.5 Fudan University4 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3 First Affiliated Hospital of Zhejiang University2
Site location
Beijing18 Guangzhou14 Shanghai8 Hefei7 Bengbu6
All 40 locations
Target enrolment
to

HER2-positive Breast Cancer trials in China

50 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
NCT07787338HER2-positive Breast Cancer
DrugTrastuzumab Rezetecan
First Affiliated Hospital of Zhejiang University
Phase 2
80
Hangzhou
2026-09
Not yet open
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-07-16
Recruiting
Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT07616440HER2-positive Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2026-06-01
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Chengdu, Fuzhou, Guangzhou, HangzhouZhejiang
2026-05-21
Recruiting
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
NCT07518173HER2-positive Breast Cancer
DrugsBL-M07D1·Pertuzumab·Trastuzumab·Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
596
Guangzhou, Chengdu
2026-04-21
Recruiting
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
NCT07647263HER2-positive Breast Cancer
DrugsPertuzumab·Trastuzumab Rezetecan·Trastuzumab
The First Affiliated Hospital of Soochow University
Phase 2
124
Suzhou
2026-03-24
Recruiting
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
NCT07377643HER2-positive Breast Cancer
DrugsIBI354·Pertuzumab·Trastuzumab·Paclitaxel
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3
540
Beijing
2026-02-10
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Not yet open
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
NCT07179939HER2-positive Breast Cancer
DrugsDalpiciclib·Pyrotinib·Trastuzumab Rezetecan·Trastuzumab
Fudan University
Phase 2
288
Shanghai
2025-09-10
Recruiting
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
NCT06892093HER2-positive Breast Cancer, Diarrhea Caused by Drug, Neratinib
DrugLoperamide
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
308
Guangzhou
2025-08-07
Recruiting
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
NCT06992882HER2-positive Breast Cancer
Fudan University
Phase 3
2,306
Shanghai
2025-07-08
Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
NCT07708194Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
DrugsEntinostat·Pyrotinib
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
94
Tianjin
2025-06-23
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT06891833HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
NCT06830889HER2-positive Breast Cancer
DrugsBL-M07D1·Trastuzumab emtansine
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
1,450
Nanjing, Shanghai
2025-06-03
Recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
NCT07358182Trastuzumab-rezetecan, HER2-low Breast Cancer, HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
300
Guangzhou
2025-06-01
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029HER2-positive Breast Cancer
DrugTrastuzumab emtansine
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
NCT06832904HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
First Affiliated Hospital of Zhejiang University
Phase 2
33
Hangzhou
2024-12-03
Not yet open
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
NCT06548178HER2-positive Breast Cancer
DrugTrastuzumab deruxtecan
Fudan University
Phase 2
242
Shanghai
2024-09
Active, closed
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06445400HER2-positive Breast Cancer
DrugsBL-M07D1·Pertuzumab·Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
83
Guangzhou
2024-06-19
Active, closed
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06316531HER2-positive Breast Cancer
DrugsBL-M07D1·Trastuzumab emtansine
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
274
Guangzhou
2024-05-08
Recruiting
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
NCT07635342HER2-positive Breast Cancer
DrugsPaclitaxel ๏ผˆAlbumin Bound๏ผ‰·Pyrotinib Maleate·Cyclophosphamide
Hebei Medical University Fourth Hospital
Phase 2
182
Shijiazhuang
2024-04-30
Recruiting
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
NCT06958627HER2 Positive Breast Cancer, Pyrotinib Treatment
DrugPyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
964
Beijing
2024-04-30
Recruiting
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086HER2-positive Breast Cancer
DrugsDP303c·Trastuzumab emtansine
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
442
Shanghai
2024-03-13
Active, closed
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
NCT06265428HER2-positive Breast Cancer
DrugsDB-1303/BNT323·Trastuzumab emtansine
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
NCT06276868Breast Cancer, HER2-positive Breast Cancer
DrugLetrozole
Henan Cancer Hospital
Phase 2
71
Henan
2024-01-20
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Recruiting
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
NCT06217185HER2-positive Breast Cancer, Advanced Breast Cancer
DrugsPyrotinib·Trastuzumab·Capecitabine
Hebei Medical University Fourth Hospital
Phase 4
100
Shijiazhuang
2024-01-02
Active, closed
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
NCT06968585HER2-positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
365
Shanghai
2023-07-18
Recruiting
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
NCT06035016HER2-positive Breast Cancer, Early-stage Breast Cancer
DrugsPyrotinib·Capecitabine
Peking Union Medical College Hospital
Observational
300
Beijing
2023-06-01
Recruiting
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
NCT05918328Breast Cancer, HER2-positive Breast Cancer
DrugsAlbumin paclitaxel·Trastuzumab·Carboplatin·Paclitaxel
Henan Cancer Hospital
Phase 2
610
Zhengzhou
2023-05-03
Recruiting
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
NCT05834764HER2-positive Breast Cancer
DrugPyrotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2
188
Nanjing
2023-04-08
Recruiting
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05635487HER2-positive Breast Cancer
DrugsPyrotinib·Trastuzumab Rezetecan
Shengjing Hospital
Phase 2
65
Shenyang
2023-03-16
Recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05760612Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2
DrugTrastuzumab and pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
300
Guangzhou
2023-03-14
Recruiting
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer, HER2-positive Breast Cancer
Hunan Cancer Hospital
Observational
200
Changsha
2023-01-01
Active, closed
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05426486HER2-positive Breast Cancer
DrugsARX788·Pyrotinib Maleate·Pertuzumab·Trastuzumab
Caigang Liu
Phase 2/3
136
Shenyang
2022-05-23
Active, closed
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjetaยฎ in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
DrugHLX11
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Maโ€™anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
DrugsTucatinib·Pertuzumab·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Recruiting
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
NCT06754059HER2-positive Breast Cancer
zhangjie
Observational
60
Fuzhou
2021-06-01
Recruiting
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
NCT04481932HER2-positive Breast Cancer
Peking University
Phase 2
104
Beijing
2020-07
Recruiting
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
NCT04281641HER2-positive Breast Cancer
Fudan University
Not applicable
94
Shanghai
2020-04-21
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
DrugsTucatinib·Trastuzumab emtansine
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
NCT06693024HER2-positive Breast Cancer
Shu Wang
Observational
2,806
Beijing
2019-01-01
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599HER2-positive Breast Cancer
Shu Wang
Observational
171
Beijing
2019-01-01
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
NCT06711068HER2-positive Breast Cancer
Shu Wang
Observational
8,077
Beijing
2019-01-01
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612HER2-positive Breast Cancer
Shu Wang
Observational
2,916
Beijing
2019-01-01
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
NCT06693037HER2-positive Breast Cancer
Shu Wang
Observational
2,092
Beijing
2019-01-01
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
NCT06700369HER2-positive Breast Cancer
Shu Wang
Observational
519
Beijing
2015-01-01
Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
NCT06711055HER2-positive Breast Cancer
Shu Wang
Observational
285
Beijing
2015-01-01
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/her2-positive-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies listing the condition HER2-positive Breast Cancer.

How many HER2-positive Breast Cancer trials are recruiting in China?

38 of the 50 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (HER2-positive Breast Cancer), 50 studies
PhaseStudiesRecruitingShare
Phase 314828%
Phase 213826%
Observational121224%
Phase 2/3438%
Not applicable336%
Phase 1/2336%
Phase 4112%

Most active sponsors

Lead sponsors with the most studies (HER2-positive Breast Cancer)
Lead sponsorStudiesRecruiting
Shu Wang77
Sichuan Baili Pharmaceutical Co., Ltd.53
Fudan University42
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University33
Beijing Biotech22
First Affiliated Hospital of Zhejiang University21
Hebei Medical University Fourth Hospital22
Henan Cancer Hospital22
Seagen, a wholly owned subsidiary of Pfizer20
Caigang Liu10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.